Newron Pharmaceuticals (Switzerland) Performance
| NWRN Stock | CHF 8.49 0.49 6.13% |
On a scale of 0 to 100, Newron Pharmaceuticals holds a performance score of 4. The company secures a Beta (Market Risk) of 0.0975, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Newron Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Newron Pharmaceuticals is expected to be smaller as well. Please check Newron Pharmaceuticals' treynor ratio, value at risk, downside variance, as well as the relationship between the maximum drawdown and potential upside , to make a quick decision on whether Newron Pharmaceuticals' current price movements will revert.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Newron Pharmaceuticals SpA are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Newron Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 13.2 M | |
| Total Cashflows From Investing Activities | 8.4 M |
Newron |
Newron Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 775.00 in Newron Pharmaceuticals SpA on September 27, 2024 and sell it today you would earn a total of 74.00 from holding Newron Pharmaceuticals SpA or generate 9.55% return on investment over 90 days. Newron Pharmaceuticals SpA is generating 0.2197% of daily returns and assumes 4.009% volatility on return distribution over the 90 days horizon. Simply put, 35% of stocks are less volatile than Newron, and 96% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Newron Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Newron Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Newron Pharmaceuticals SpA, and traders can use it to determine the average amount a Newron Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0548
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NWRN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.01 actual daily | 35 65% of assets are more volatile |
Expected Return
| 0.22 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 4 96% of assets perform better |
Based on monthly moving average Newron Pharmaceuticals is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Newron Pharmaceuticals by adding it to a well-diversified portfolio.
Newron Pharmaceuticals Fundamentals Growth
Newron Stock prices reflect investors' perceptions of the future prospects and financial health of Newron Pharmaceuticals, and Newron Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Newron Stock performance.
| Return On Equity | -8.4 | |||
| Return On Asset | -0.16 | |||
| Profit Margin | (2.44) % | |||
| Operating Margin | (1.84) % | |||
| Current Valuation | 32.84 M | |||
| Shares Outstanding | 17.85 M | |||
| Price To Earning | (11.88) X | |||
| Price To Book | 7.98 X | |||
| Price To Sales | 3.95 X | |||
| Revenue | 5.76 M | |||
| EBITDA | (11.76 M) | |||
| Cash And Equivalents | 58.99 M | |||
| Cash Per Share | 3.31 X | |||
| Total Debt | 42.93 M | |||
| Debt To Equity | 0.70 % | |||
| Book Value Per Share | (0.29) X | |||
| Cash Flow From Operations | (11.45 M) | |||
| Earnings Per Share | (0.85) X | |||
| Total Asset | 50.49 M | |||
About Newron Pharmaceuticals Performance
Evaluating Newron Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Newron Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Newron Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system in Italy and internationally. The company was founded in 1998 and is headquartered in Bresso, Italy. NEWRON PHARMA operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 24 people.Things to note about Newron Pharmaceuticals performance evaluation
Checking the ongoing alerts about Newron Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Newron Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Newron Pharmaceuticals had very high historical volatility over the last 90 days | |
| Newron Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 5.76 M. Net Loss for the year was (14.9 M) with profit before overhead, payroll, taxes, and interest of 5.76 M. | |
| Newron Pharmaceuticals SpA has accumulated about 58.99 M in cash with (11.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.31. |
- Analyzing Newron Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Newron Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Newron Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Newron Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Newron Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Newron Pharmaceuticals' stock. These opinions can provide insight into Newron Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Newron Stock Analysis
When running Newron Pharmaceuticals' price analysis, check to measure Newron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Newron Pharmaceuticals is operating at the current time. Most of Newron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Newron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Newron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Newron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.